CORT

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 16, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, RBB, Agrify, and Corcept and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, August 11, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Medallions stock fell up to 27% during intraday trading on December 29, 2021, thereby injuring investors.
  • For more information on the Corcept investigation go to: https://bespc.com/cases/CORT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Hannon Armstrong, NIO, and Generac and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, August 6, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Corcepts stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.
  • For more information on the Generac investigation go to: https://bespc.com/cases/GNRC
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 3, 2022 - 9:05pm

Diluted net income per common share of $0.24, compared to $0.21 in second quarter 2021

Key Points: 
  • Diluted net income per common share of $0.24, compared to $0.21 in second quarter 2021
    Cash and investments of $382.0 million, compared to $368.1 million at March 31, 2022
    Corcepts second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021.
  • Second quarter operating expenses were $72.0 million, compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and commercial teams and legal fees.
  • Net income was $27.4 million in the second quarter of 2022, compared to $26.5 million in the second quarter of 2021.
  • Cash and investments increased $13.9 million in the second quarter, to $382.0 million at June 30, 2022.

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Corcept, Cassava, and Hannon Armstrong and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, August 1, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Carvanas stock price fell $6.55 per share, or 15.75%, to close at $35.05 per share on May 18, 2022.
  • For more information on the Hannon Armstrong investigation go to: https://bespc.com/cases/HASI
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Retrieved on: 
Wednesday, July 27, 2022 - 9:05pm

MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 3, 2022.

Key Points: 
  • MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 3, 2022.
  • The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
  • Participants must register in advance of the conference call by clicking here .
  • Upon registering, each participant will receive a dial-in number, and a unique access PIN.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Cassava, and Hannon Armstrong and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 26, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Hannon Armstrong investigation go to: https://bespc.com/cases/HASI
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Rollins, and the WWE and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, July 21, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the WWE investigation go to: https://bespc.com/cases/WWE
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Enochian, Corcept, Rollins, and Target and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Enochians stock fell $2.17, or 37%, to close at $3.70 per share on May 25, 2022.
  • Dr. Gumrukcu sold 253,493 shares of Enochian stock on May 18, 2022, for a total value of over $2 million.
  • For more information on the Target investigation go to: https://bespc.com/cases/TGT
    About Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Is Investigating Corcept, Rollins, Target, and TG Therapeutics and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 11, 2022 - 2:00am

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, TG Therapeutics' stock price fell $8.16 per share, or 34.93%, to close at $15.20 per share on November 30, 2021.
  • For more information on the TG Therapeutics investigation go to: https://bespc.com/cases/TGTX
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.